2. It can prevent the misuse of zolpidem containing the inhibitor of zolpidem in the oral cavity, the purpose of which is to prevent the abuse of tablets at the cost of the third requirement 1: perfluorooctane sulfonic acid； It is characterized by the presence of zolpidem or a pharmaceutically acceptable salt thereof, at least one pathogenic agent, and at least one soluble polymer and component, if the compression agent enters the final alcoholic beverage,The visual media they produce is equivalent to the opacity of drinks, at least another visual media selected between the formation of anesthetics, insoluble particles, the floating of ingredients and the combination of these visual media, Learn about the opaque ingredient titanium dioxide particles that cause this drink. Claim 11: compression according to any one of claims 1 to 10, which is characterized by comprising (1) a polymer containing particles coated with zolpidem and a soluble polymer with a pH of 5 or lower as a coating agent and permeable to a pH above 5,(2) External stage, including at least one irreversible agent, at least one polyol soluble agent, if the compression agent enters the final alcoholic beverage, They produce a visual medium equivalent to the opacity of drinks, at least another alternative visual medium, between the formation of compressed anesthetics, compressed floats, insoluble particles, and the combination of these visual media, It is the opaque component of the drink, the carbon dioxide particle titanium.Formas farmacéuticas orales con disgregación rápida y que permiten evitar un mal uso eventual del zolpidem que contienen formulación de comprimido orodispersable a base de zolpidem destinada a evitar el uso indebido del comprimido a costa de un tercero.Reivindicación 1: Comprimido farmacéutico orodispersable, caracterizado porque comprende zolpidem o una de sus sales farmacéuticamente aceptables, al menos un agente disgregante, al menos un agente soluble de tipo poliol y componentes
